Bionomics Investor Webinar
14 June 2022 - 6:30AM
Bionomics Limited (ASX: BNO |Nasdaq: BNOX ),
(
Bionomics or the
Company), a
clinical-stage biopharmaceutical company developing novel,
allosteric ion channel modulators designed to transform the lives
of patients suffering from serious central nervous system (CNS)
disorders with high unmet medical need, invites shareholders and
interested parties to attend an investor webinar with Executive
Chairman Dr. Errol De Souza and Vice President of Strategy and
Corporate Development Mr. Connor Bernstein, at 10.30am (AEST) on
Wednesday 15 June 2022 (or in the U.S. at 8.30pm (ET) on Tuesday 14
June 2022).
The presentation will cover Bionomics’ ongoing Phase 2 trials
for Social Anxiety Disorder (SAD) and Post-Traumatic Stress
Disorder (PTSD) and the pressing need for new treatments for
patients suffering from these disorders. The presenters will also
discuss the Company’s near-term milestones and goals for 2022 and
beyond.
Please follow this link to register for the webinar:
https://us06web.zoom.us/webinar/register/WN_OzE5MYuTRMiRi98-8AcXgQ
The presentation will also be made available on the Bionomics
website.
Released on authority of the Executive Chairman.
FOR FURTHER INFORMATION PLEASE CONTACT:
General: Ms
Suzanne Irwin Company Secretary +61 8 8150 7400
CoSec@bionomics.com.au |
Investor
Relations: Mr. Connor BernsteinVice President, Strategy
and Corporate Development +1 (650) 524-5143
cbernstein@bionomics.com.au |
About Bionomics Limited
Bionomics (ASX:BNO, NASDAQ:BNOX) is a clinical-stage
biopharmaceutical company developing novel, allosteric ion channel
modulators designed to transform the lives of patients suffering
from serious central nervous system (CNS) disorders with high unmet
medical need. Bionomics is advancing its lead drug candidate,
BNC210, an oral, proprietary, selective negative allosteric
modulator of the α7 nicotinic acetylcholine receptor, for the acute
treatment of Social Anxiety Disorder (SAD) and chronic treatment of
Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has
a strategic partnership with Merck & Co., Inc (known as MSD
outside the United States and Canada) with two drugs in early-stage
clinical trials for the treatment of cognitive deficits in
Alzheimer’s disease and other central nervous system conditions.
www.bionomics.com.au
Factors Affecting Future Performance
This announcement contains “forward-looking”
statements within the meaning of the U.S. federal securities laws.
Any statements contained in this announcement that relate to
prospective events or developments, including, without limitation,
statements related to the Offering are deemed to be forward-looking
statements. Words such as “believes,” “anticipates,” “plans,”
“expects,” “projects,” “forecasts,” “will” and similar expressions
are intended to identify forward-looking statements. There are a
number of important factors that could cause actual results or
events to differ materially from those indicated by these
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events, or otherwise. Actual results
could differ materially from those discussed in this ASX
announcement.
Bionomics (NASDAQ:BNOX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Bionomics (NASDAQ:BNOX)
Historical Stock Chart
From Dec 2023 to Dec 2024